Navigation Links
Valeant Pharmaceuticals Annonces New $1.5 Billion Securites Repurchase Program
Date:11/19/2012

MONTREAL, Nov. 19, 2012 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) announced today that its board of directors has authorized a new securities repurchase program (the "Securities Repurchase Program"). Under the Securities Repurchase Program, which commenced November 15, 2012, the Company may make purchases of up to $1.5 billion of its senior notes, common shares and/or other debt or shares that may be issued prior to the completion of the program. The Securities Repurchase Program will replace the Company's former securities repurchase program, which expired on November 7, 2012.

Valeant's Board of Directors also approved a sub-limit for the repurchase of Valeant common shares of the greater of 10% of the Company's public float or 5% of the Company's issued and outstanding common shares, in each case calculated as of the date of the commencement of the Securities Repurchase Program. On the date of the commencement of the Securities Repurchase Program, the Company had approximately 303,442,994 common shares outstanding. Valeant intends to initially make purchases of up to 15,172,149 common shares on the open market through the facilities of the New York Stock Exchange (NYSE), representing approximately 5% of the Company's issued and outstanding common shares. Subject to completion of appropriate filings with and approval by the Toronto Stock Exchange (TSX), the Company may also make purchases of its common shares over the facilities of the TSX. Such purchases of common shares will be made at prevailing market prices of such shares on the NYSE or the TSX, as the case may be, at the time of the acquisition and shall be made in accordance with the respective rules and guidelines of the NYSE and the TSX. All common shares purchased under the Securities Repurchase Program will be cancelled.

The amount of securities to be purchased and the timing of purchases under the Securities Repurchase Program may be subject to various factors, which may include the price of the securities, general market conditions, corporate and regulatory requirements, alternate investment opportunities and restrictions under the Company's financing agreements. The securities to be repurchased will be funded using Valeant's cash resources. The Securities Repurchase Program will terminate on November 14, 2013 or at such time as Valeant completes its purchases. The program does not require Valeant to repurchase a minimum number of securities, and the Securities Repurchase Program may be modified, suspended or terminated at any time without prior notice. Valeant's Board of Directors believes that the proposed purchases are in the best interests of the Company and are a desirable use of corporate funds.

On November 8, 2011, Valeant commenced its former securities repurchase program, which terminated on November 7, 2012. Under that securities repurchase program, the Company purchased 6,792,311 of its common shares for aggregate consideration of $345.8 million, a total of $2.4 million principal amount of its 5.375% Convertible Notes for aggregate consideration of $7.9 million, a total of $34.5 million principal amount of its 6.50% Senior Notes due 2016 for aggregate consideration of $34.3 million, a total of $45.4 million principal amount of its 6.875% Senior Notes due 2018 for aggregate consideration of $45.0 million and a total of $10.0 million principal amount of its 7.00% Senior Notes due 2020 for aggregate consideration of $9.5 million.

About Valeant
Valeant Pharmaceuticals International, Inc. (NYSE/TSX:VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, neurology and branded generics. More information about Valeant can be found at www.valeant.com.

Forward-looking Statements
This press release may contain forward-looking statements, including, but not limited to, the Company's intention to repurchase its debt and equity securities.  Forward-looking statements may generally be identified by the use of the words "anticipates," "expects," "intends," "plans," "should," "could," "would," "may," "will," "believes," "estimates," "potential," "target", or "continue" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, market factors affecting the price and liquidity of debt and equity securities, the satisfaction by Valeant of applicable laws to allow it to repurchase its securities, the availability of capital including the amount of cash generated from Valeant's business, the existence of alternative uses for Valeant's cash and the risk factors as detailed from time to time in Valeant's reports filed with the Securities and Exchange Commission and the Canadian Securities Administrators.

The Company cautions that the foregoing list of important factors that may affect future results is not exhaustive. When relying on Valeant's forward-looking statements to make decisions with respect to the Company, investors and others should carefully consider the foregoing factors and other uncertainties and potential events. Valeant undertakes no obligation to update or revise any forward-looking statement, except as required by law.

(Logo:  http://photos.prnewswire.com/prnh/20101025/LA87217LOGO)

Contact Information:
Laurie W. Little
949-461-6002
laurie.little@valeant.com


'/>"/>
SOURCE Valeant Pharmaceuticals International, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Valeant Pharmaceuticals Receives FTC Clearance For Medicis Acquisition
2. Valeant Pharmaceuticals Reports 2012 Third Quarter Financial Results
3. Valeant Pharmaceuticals Reschedules Its Third Quarter 2012 Financial Results Webcast And Conference Call To November 2, 2012 Due To Hurricane Sandy
4. Valeant Pharmaceuticals International, Inc. Announces Pricing Of Concurrent Private Offerings Of Senior Notes
5. Valeant Pharmaceuticals Announces Launch of Concurrent Private Offerings of Senior Notes
6. Valeant Pharmaceuticals Appoints Howard Schiller To Board Of Directors
7. Valeant Pharmaceuticals To Syndicate Incremental Loans
8. Valeant Pharmaceuticals Announces Management Change
9. Valeant Pharmaceuticals To Present At UBS Annual Global Life Sciences Conference
10. Valeant Pharmaceuticals International, Inc. Agrees To Acquire Medicis Pharmaceutical Corporation For $44.00 Per Share In Cash
11. Valeant Pharmaceuticals To Announce 2012 Second Quarter Results On August 2, 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... SOUTH SAN FRANCISCO, Calif. , June 24, ... GBT ), a biopharmaceutical company developing novel ... with significant unmet needs, today announced the closing ... 6,400,000 shares of common stock, at the public ... the shares in the offering were offered by ...
(Date:6/24/2016)... , June 24, 2016 ... Markets has announced the addition of the " ... offering. This ... and provides an updated review, including its applications in ... the total market, which includes three main industries: pharmaceutical ...
(Date:6/24/2016)... 24, 2016 The Academy of Managed Care ... that would allow biopharmaceutical companies to more easily ... make formulary and coverage decisions, a move that addresses ... medicines. The recommendations address restrictions in the ... the drug label, a prohibition that hinders decision makers ...
Breaking Medicine Technology:
(Date:6/26/2016)... California (PRWEB) , ... June 26, 2016 , ... Pixel ... Cut Pro X. , "Film editors can give their videos a whole new perspective ... Christina Austin - CEO of Pixel Film Studios. , ProSlice Levels contains over ...
(Date:6/25/2016)... Austin, TX (PRWEB) , ... June 25, 2016 , ... ... Fellow of the American College of Mohs Surgery and to Dr. Russell Peckham for ... popular and highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has ... he has implemented orthobiologic procedures as a method for treating his patients. The ... first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World ... with chronic pain and the benefits of holistic treatments, Serenity Recovery Center ... with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of the ...
(Date:6/24/2016)... Diego, CA (PRWEB) , ... June 24, 2016 , ... ... with the American Cancer Society and the Road To Recovery® program to drive cancer ... to seniors and other adults to ensure the highest quality of life and ongoing ...
Breaking Medicine News(10 mins):